



Reminder: Prior Authorization Policy Updates

February 6, 2026

Background

As previously announced in the alert titled [Changes to Medi-Cal Rx, Effective January 1, 2026](#) and pursuant to the enacted [2025-26 State Budget](#), the Department of Health Care Services (DHCS) implemented a series of Medi-Cal Rx policy updates on January 1, 2026, to reduce pharmacy spending, improve program integrity, and ensure continued, equitable access to quality pharmacy benefits and services.

What Pharmacy Providers and Prescribers Need to Know

The following drugs and drug classes are not eligible for extended duration prior authorizations (PAs). Claims submitted for these drugs without an approved PA will deny with **Reject Code 75 – Prior Authorization Required**. Pharmacy providers and prescribers must submit a PA request for coverage consideration.

Impacted Drugs		
Antihyperlipidemic Agents		
Juxtapid® (lomitapide)	Tryngolza™ (olezarsen sodium)	Nexlizet® (bempedoic acid/ezetimibe)
Nexletol® (bempedoic acid)	Livalo® (pitavastatin calcium) Zypitamag® (pitavastatin magnesium)	Atorvaliq® (atorvastatin calcium oral suspension)
Altacor™ Altoprev® (lovastatin)	Fluvastatin sodium 20 mg, 40 mg capsules Lescol XL® (fluvastatin sodium extended-release tablet)	Ezallor Sprinkle® (rosuvastatin calcium)
FloLipid® Oral Susp (simvastatin oral suspension)		

Impacted Drugs		
Anti-Inflammatory Agents		
Naproxen 500 mg delayed-release tablet Naproxen sodium 220 mg, 275 mg, 550 mg Etodolac (all strengths) Ibuprofen drops	Celebrex® (celecoxib) 50 mg, 400 mg capsule	Pennsaid® Klofensaid (diclofenac sodium topical 1.5%)
Duexis (ibuprofen/famotidine)		
Miscellaneous Drugs		
Alyftrek® (vanzacaftor/tezacaftor/deutivacaftor)	Daybue® (trofinetide)	Gattex® (teduglutide)
Crenessity™ (crinicerfont)	Vyvgart® Hytrulo™ (efgartigimod/hyaluronidase /qvc)	Vyvgart (efgartigimod alfa-fcab)
Revcovi® (elapegademase-lvlr)	Rystiggo® (rozanolixizumab-noli)	Crysvita® (burosumab-twza)
Xywav® (calcium, magnesium, potassium, and sodium oxybates)	Xyrem® (sodium oxybate)	Vyjuvek® (beremagene geperpavec-svdt)
Cystagon® Procysbi® (cysteamine bitartrate)	Skyclarys™ (omaveloxolone)	Evkeeza® (evinacumab-dgnb)
Vykat XR™ (diazoxide choline)	Pyrukynd® (mitapivat sulfate)	Kalydeco® (ivacaftor)
Kuvan® Javygtor™ Zelvysia™ (sapropterin dihydrochloride)	Orkambi® (lumacaftor/ivacaftor)	Trikafta® (elexacaftor/tezacaftor/ivacaftor)
Symdeko® (tezacaftor/ivacaftor)	Palynziq® (pegvaliase-pqpz)	

In addition, to satisfy utilization management (UM) claim edits and PA requirements, and to align with *California Code of Regulations (CCR)*, Title 22, Section 51003(e), Medi-Cal Rx policy utilizes a lookback period for paid claims history of 100 days and up to a 12-month PA approval period. Certain requests may be considered for a longer approval length on a case-by-case basis, dependent on meeting medical necessity and aligning with the CCR. Historical PA approvals from managed care plans (MCPs), Medi-Cal fee-for-service (FFS), and Children's Medical Services (CMS) Net are not valid outside the approval period or if paid claims history is greater than 100 days and therefore a new PA request may be needed.

What Pharmacy Providers and Prescribers Need to Do

- Refer to the [Contract Drugs & Covered Products Lists](#) page on the [Medi-Cal Rx Web Portal](#) for information regarding drugs/products eligible for coverage under Medi-Cal Rx as a pharmacy benefit and Code I limitations.
- Consider alternate covered therapies that may not require a PA request, if clinically appropriate. Refer to the [Medi-Cal Rx Approved NDC List](#) on the [Medi-Cal Rx Web Portal](#).
- If a change in therapy is not appropriate, submit a PA request via one of the approved Medi-Cal Rx submission methods. Refer to the [Prior Authorization Submission Reminders](#) and [Reminder: Establishing Medical Necessity](#) alerts.
- Review PA resources by selecting the **Prior Authorization (PA)** tab on the [Forms & Information](#) page.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at MediCalRxEducationOutreach@primetherapeutics.com.